These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9879329)

  • 1. [Observance, adherence, compliance ...different words for better therapeutic results].
    Baril L
    Presse Med; 1998 Dec; 27 Suppl 5():13-4. PubMed ID: 9879329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplifying drug regimens.
    HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
    Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
    J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
    Saah AJ; Haas DW; DiNubile MJ; Chen J; Holder DJ; Rhodes RR; Shivaprakash M; Bakshi KK; Danovich RM; Graham DJ; Condra JH
    J Infect Dis; 2003 Apr; 187(7):1157-62. PubMed ID: 12660932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to switch and what to switch to: strategic use of antiretroviral therapy.
    Gulick R
    AIDS Read; 2000 Mar; 10(3):156-61; discussion 171-4. PubMed ID: 10758015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications.
    Miller LG; Hays RD
    AIDS Read; 2000 Mar; 10(3):177-85. PubMed ID: 10758022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data on nevirapine combinations released.
    AIDS Patient Care STDS; 1998 Apr; 12(4):316-7. PubMed ID: 11361960
    [No Abstract]   [Full Text] [Related]  

  • 14. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell activation: a cellular target for antiretroviral therapy.
    Fidler S; Weber J
    Eur J Clin Invest; 2000 Feb; 30(2):95-8. PubMed ID: 10651832
    [No Abstract]   [Full Text] [Related]  

  • 16. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance.
    Richman DD
    Adv Exp Med Biol; 1996; 394():383-95. PubMed ID: 8815703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.
    Walmsley SL; Becker MI; Zhang M; Humar A; Harrigan PR
    Antivir Ther; 2001 Mar; 6(1):47-54. PubMed ID: 11417761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of nelfinavir in the triple-therapy of HIV infection].
    Coulaud JP
    Presse Med; 1999 Feb; 28(7):368-70. PubMed ID: 10083885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.